A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.
Authors
Wong, RCunningham, D
Barbachano, Y
Saffery, C
Valle, Juan W
Hickish, T
Mudan, S
Brown, G
Khan, A
Wotherspoon, A
Strimpakos, A S
Thomas, J
Compton, S
Chua, Y J
Chau, I
Affiliation
Department of Medicine, Royal Marsden Hospital NHS Foundation Trust, Sutton, UK.Issue Date
2011-09
Metadata
Show full item recordAbstract
Perioperative chemotherapy improves outcome in resectable colorectal liver-only metastasis (CLM). This study aimed to evaluate perioperative CAPOX (capecitabine-oxaliplatin) plus bevacizumab in patients with poor-risk CLM not selected for upfront resection.Citation
A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. 2011, 22 (9):2042-8 Ann OncolJournal
Annals of OncologyDOI
10.1093/annonc/mdq714PubMed ID
21285134Type
ArticleLanguage
enISSN
1569-8041ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdq714
Scopus Count
Related articles
- A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment.
- Authors: Snoeren N, Voest EE, Bergman AM, Dalesio O, Verheul HM, Tollenaar RA, van der Sijp JR, Schouten SB, Rinkes IH, van Hillegersberg R
- Issue date: 2010 Oct 11
- Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection.
- Authors: Dewdney A, Cunningham D, Barbachano Y, Chau I
- Issue date: 2012 May 22
- Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open-label, single-arm, noncomparative trial.
- Authors: Chen HH, Lin JK, Chen JB, Chuang CH, Liu MC, Wang JY, Changchien CR
- Issue date: 2018 Feb
- Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
- Authors: Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F, Gruenberger T
- Issue date: 2008 Apr 10
- Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection.
- Authors: Constantinidou A, Cunningham D, Shurmahi F, Asghar U, Barbachano Y, Khan A, Mudan S, Rao S, Chau I
- Issue date: 2013 Mar